ABPI response to EU data adequacy decision

The European Commission has issued a positive preliminary data adequacy decision for the UK which will allow data to continue to flow freely from the EU to the UK.

The free flow of data is fundamental to the continued success of our sector and the ability of our scientists to deliver new breakthroughs for patients. Dr Bryan Deane

Data adequacy is crucial for cross-border research and clinical trials to continue without additional burden.

Patient data and test results, for example, need to be routinely transferred across international borders as part of ongoing studies.

In response, Dr Bryan Deane, Data Policy Director at the ABPI, said:

“The free flow of data is fundamental to the continued success of our sector and the ability of our scientists to deliver new breakthroughs for patients.

“We welcome today’s decision and urge the European Data Protection Board to support it so that business can have certainty about the rules that will govern UK-EU data transfers going forward.”

 

TAGS
  • Health data

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.